Double-fluorescence report system and application thereof
Through the nucleic acid molecules of the dual fluorescence reporter system, the screening process of sgRNA is simplified by luciferase or fluorescent protein, solving the problem of screening complexity in single-base editing, and achieving the effect of rapid evaluation of gene editing efficiency.
Patent Information
- Application Number
- CN202411221700.3
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-09-02
- Publication Date
- 2024-11-26
AI Technical Summary
In single-base editing, the process of screening sgRNA is complicated and lacks convenient and fast means, and the process of knocking fluorescent protein genes into the genome is inconvenient, which limits the application of fluorescent proteins in the field of gene editing.
A dual fluorescence reporter system is proposed. By containing luciferase or fluorescent proteins encoding the first and second reporter proteins, the limitation of sgRNA screening on cell types is reduced, and the gene editing efficiency is quickly judged through fluorescence, simplifying screening. step.
Efficient screening of sgRNA is achieved, which reduces the complexity of the experiment, and quickly evaluates gene editing efficiency through fluorescence expression, improving the efficiency of screening tests.
Smart Images

Figure SMS_1 
Figure SMS_2 
Figure SMS_3
Abstract
Description
Technical Field
[0001] The invention belongs to the field of biotechnology, and in particular relates to a dual fluorescence reporter system and application thereof. Background Art
[0002] Single-base editing is a form of genome editing that can directly convert a single nucleotide at a specific genomic site without introducing double-stranded DNA breaks. It has great potential as a therapeutic tool for correcting gene mutations. There are many reports on the use of single-base editors to correct gene mutations in animal disease models at the genetic level. Common single-base editors include nCas9-linked deaminases. Under the guidance of sgRNA, nCas9-linked deaminases locate the target genomic location and play a role.
[0003] However, there is still a lack of convenient and fast means to screen the sgRNA required for single-base editing; at the same time, screening experiments require the use of patient cells or specially constructed cell models, which increases the complexity of the experiment, so a more convenient screening method needs to be developed.
[0004] Fluorescent proteins have a wide range of applications in many areas of biological research, including gene editing. Fluorescent proteins of various colors have been developed, among which EGFP and mCherry can be detected on almost all fluorescence microscopes and flow cytometers, and are therefore widely used. By fusing the fluorescent protein gene with the target gene, the expression of the target gene can be observed. However, for genome editing, there are many inconveniences in knocking the fluorescent protein gene into the genome, which limits the use of fluorescent proteins in this regard. Summary of the invention
[0005] The present invention aims to solve at least one of the technical problems existing in the above-mentioned prior art. To this end, the present invention proposes a dual fluorescence reporter system, and specifically provides a nucleic acid molecule included in the dual fluorescence reporter system, which reduces the restriction on cell types in sgRNA screening experiments, and can quickly judge the gene editing efficiency of sgRNA by fluorescence, greatly simplifying the steps required for screening sgRNA.
[0006] The present invention also provides a biomaterial.
[0007] The present invention also provides a kit.
[0008] The present invention also provides an application.
[0009] The present invention also provides a method for screening sgRNA.
[0010] According to a first aspect of the present invention, a nucleic acid molecule is provided, which comprises, from the 5' end to the 3' end, a first reporter gene encoding a first reporter protein, a target gene fragment, and a second reporter gene encoding a second reporter protein.
[0011] In some embodiments of the present invention, the first reporter protein and the second reporter protein each independently include a luciferase protein or a fluorescent protein. In some preferred embodiments of the present invention, the luciferase protein is selected from any one of firefly luciferase, Renilla luciferase and Gaussia luciferase.
[0012] In some preferred embodiments of the present invention, the fluorescent protein is selected from any one of green fluorescent protein, blue fluorescent protein, yellow fluorescent protein and red fluorescent protein.
[0013] In some more preferred embodiments of the present invention, the green fluorescent protein includes GFP or EGFP.
[0014] In some more preferred embodiments of the present invention, the blue fluorescent protein is selected from any one of EBFP2, mTagBFP, SBFP2, mTurquoise2 and Cerulean.
[0015] In some more preferred embodiments of the present invention, the red fluorescent protein is selected from any one of mCherry, tdTomato, DsRed, mStrawberry and mApple.
[0016] In some preferred embodiments of the present invention, the first reporter protein and the second reporter protein are different from each other.
[0017] In some more preferred embodiments of the present invention, the first reporter protein is red fluorescent protein.
[0018] In some more preferred embodiments of the present invention, the first reporter protein is mCherry.
[0019] In some more preferred embodiments of the present invention, the second reporter protein is green fluorescent protein.
[0020] In some more preferred embodiments of the present invention, the second reporter protein is EGFP.
[0021] In some embodiments of the present invention, the nucleotide sequence of the nucleic acid molecule is shown in SEQ ID NO:5.
[0022] According to a second aspect of the present invention, a biomaterial is provided, wherein the biomaterial comprises at least one of the following (1) to (7):
[0023] (1) an expression cassette comprising the nucleic acid molecule described in the first aspect of the present invention;
[0024] (2) a vector comprising the nucleic acid molecule described in the first aspect of the present invention;
[0025] (3) a vector comprising the expression cassette described in (1);
[0026] (4) a transgenic cell line comprising the nucleic acid molecule described in the first aspect of the present invention;
[0027] (5) a transgenic cell line comprising the expression cassette described in (1);
[0028] (6) a transgenic cell line comprising the vector described in (2);
[0029] (7) A transgenic cell line comprising the vector described in (3).
[0030] In some embodiments of the invention, the transgenic cell line does not contain reproductive material.
[0031] In some embodiments of the present invention, the vector comprises a pCMV plasmid vector.
[0032] According to the third aspect of the present invention, a kit is provided, which comprises: the nucleic acid molecule according to the first aspect of the present invention and / or the biological material according to the second aspect of the present invention.
[0033] In some embodiments of the present invention, the kit further comprises a nucleic acid molecule encoding a base editing element and a gene editing enzyme.
[0034] In some preferred embodiments of the present invention, the base editing element comprises adenine deaminase or cytosine deaminase.
[0035] In some more preferred embodiments of the present invention, the base editing element is adenine deaminase.
[0036] In some preferred embodiments of the present invention, the gene editing enzyme includes nCas9.
[0037] According to the fourth aspect of the present invention, the application of (a) to (c) in evaluating sgRNA-mediated gene editing activity is proposed:
[0038] (a) the nucleic acid molecule according to the first aspect of the present invention;
[0039] (b) the biomaterial according to the second aspect of the present invention;
[0040] (c) The kit according to the third aspect of the present invention.
[0041] According to a fifth aspect of the present invention, a method for screening sgRNA is provided, wherein the method uses the kit as described in the third aspect of the present invention to screen the sgRNA to be tested.
[0042] In some embodiments of the invention, the method comprises the following steps:
[0043] An expression vector containing the nucleic acid molecule as described in the first aspect of the present invention, an expression vector encoding a base editing element and a gene editing enzyme, and an expression vector encoding the sgRNA to be tested are co-transfected into a host cell and cultured; the fluorescence expression of the host cell is then detected to evaluate the gene editing activity of the sgRNA.
[0044] The present invention has at least the following beneficial effects:
[0045] The dual fluorescence reporter system provided by the present invention can be used for sgRNA screening, and has no restrictions on the cell types used in the screening test; at the same time, the gene editing efficiency can be quickly judged by the expression of fluorescent proteins, which greatly improves the efficiency of the screening test. BRIEF DESCRIPTION OF THE DRAWINGS
[0046] The present invention will be further described below with reference to the accompanying drawings and embodiments, wherein:
[0047] Figure 1 This is a schematic diagram of the plasmid pEGFP-N2-5 in Example 1 of the present invention;
[0048] Figure 2 This is a schematic diagram of the plasmid pmCherry-FBN1-23bp-EGFP in Example 1 of the present invention;
[0049] Figure 3 This is a schematic diagram of the plasmid pEGFP-fbn1-45bp-2xP2A in Example 1 of the present invention;
[0050] Figure 4 This is a schematic diagram of the target sequence of the FBN1 gene in Example 1 of the present invention, wherein the base portion marked in red is the stop codon;
[0051] Figure 5 Schematic diagram of plasmid pU6-gRNA in the test example of the present invention;
[0052] Figure 6 This is a graph showing the results of Sanger sequencing of sgRNA in the experimental example of the present invention;
[0053] Figure 7 Schematic diagram of plasmid pCMV-SpRY-ABE8e in the test example of the present invention;
[0054] Figure 8The fluorescence microscopy result diagram of HEK293T cells after transfection in the experimental example of the present invention, wherein the scale bar is 100μ0;
[0055] Fig. 9 The fluorescence microscopy result diagram of HEK293T cells after transfection in the experimental example of the present invention, wherein the scale bar is 100 μm;
[0056] Fig.10 It is a statistical graph of the ratio of the number of green fluorescent cells to the number of red fluorescent cells in the test example of the present invention;
[0057] Fig.11 Figure 1 is a diagram of the gene editing effects of different plasmid combinations in the test examples of the present invention, and is the Sanger sequencing result;
[0058] Fig.12 This is a graph showing the gene editing efficiency results of different plasmid combinations in the test examples of the present invention. DETAILED DESCRIPTION
[0059] The following will be combined with the embodiments to clearly and completely describe the concept of the present invention and the technical effects produced, so as to fully understand the purpose, characteristics and effects of the present invention. Obviously, the described embodiments are only part of the embodiments of the present invention, not all of them. Based on the embodiments of the present invention, other embodiments obtained by those skilled in the art without creative work are all within the scope of protection of the present invention.
[0060] In the description of the present invention, "several" means more than one, "many" means more than two, "greater than", "less than", "exceed", etc. are understood to exclude the number itself, and "above", "below", "within", etc. are understood to include the number itself. If there is a description of "first" or "second", it is only used for the purpose of distinguishing the technical features, and cannot be understood as indicating or implying the relative importance or implicitly indicating the number of the indicated technical features or implicitly indicating the order of the indicated technical features.
[0061] Example 1
[0062] This embodiment provides a dual fluorescence reporter system, and the construction method of the dual fluorescence reporter system specifically includes the following steps:
[0063] 1) Transfect the backbone plasmid pEGFP-N2-5 (constructed in the laboratory, the plasmid map is as follows Figure 1 The restriction endonuclease HindIII was used for digestion, and the specific digestion system is shown in Table 1;
[0064] The enzyme digestion was carried out in a 37°C water bath for 5 hours, and then agarose gel electrophoresis was performed. The 5400 bp enzyme digestion product was recovered using a gel recovery kit (TIANGEN) to obtain the linearized backbone plasmid pEGFP-N2-5.
[0065] Table 1 Enzyme digestion system 1
[0066] Components content pEGFP-N2-5 3μg HindIII(Takara) 2.5μL 10×Buffer 4μL <![CDATA[ddH 2 The]]> Make up to 40 μL
[0067] 2) Using the backbone plasmid pUC-GW-Kan (constructed in the laboratory) as a template, PCR amplification was performed with primers p1-1 and p1-2 (specific sequences are shown in Table 2), and the amplification system is shown in Table 3; then agarose gel electrophoresis was performed, and the PCR product was recovered using a gel recovery kit (TIANGEN).
[0068] Table 2 Primer sequence 1
[0069]
[0070] Table 3 PCR system 1
[0071]
[0072]
[0073] 3) The linearized backbone plasmid pEGFP-N2-5 obtained in step 1) and the PCR product obtained in step 2) were recombined using a recombinase and incubated at 50° C. for 20 min. The specific recombination system is shown in Table 4.
[0074] Table 4 Recombination system 1
[0075] Components content Linearized backbone plasmid pEGFP-N2-5 108ng PCR products 11ng Clone Express mix (Vazyme) 5μL <![CDATA[ddH 2 The]]> Make up to 10 μL
[0076] 4) Transform the recombinant product prepared in step 3) and pick a single clone to obtain the plasmid pmCherry-FBN1-23bp-EGFP (plasmid map as shown in Figure 2 shown).
[0077] 5) The backbone plasmid pmCherry-FBN1-23bp-EGFP obtained in step 4) was digested with restriction endonuclease HindIII. The digestion system is shown in Table 5. The digestion was carried out in a 37°C water bath for 5 hours, and then agarose gel electrophoresis was performed. The 5900bp digestion product was recovered using a gel recovery kit (TIANGEN).
[0078] Table 5 Enzyme Digestion System 2
[0079] Components content pmCherry-FBN1-23bp-EGFP 3μg HindIII(Takara) 2.5μL 10×Buffer 4μL <![CDATA[ddH 2 The]]> Make up to 40 μL
[0080] 6) PCR amplification was performed using primers p2-1 and p2-2 (specific sequences are shown in Table 6) as templates for each other, and the amplification system is shown in Table 7; then agarose gel electrophoresis was performed, and the PCR product was recovered using a gel recovery kit (TIANGEN).
[0081] Table 6 Primer sequence 2
[0082]
[0083]
[0084] Table 7 PCR system 2
[0085] Components content p2-1 2μL p2-2 2μL Prime STAR max(Takara) 20μL <![CDATA[ddH 2 The]]> Make up to 40 μL
[0086] 7) The enzyme digestion product obtained in step 5) and the PCR product in step 6) were recombined with a recombinase and incubated at 50° C. for 20 min. The recombinant system is shown in Table 8.
[0087] Table 8 Recombination system 2
[0088] Components content Step 5) Enzyme digestion product 118ng PCR product of step 6) 2ng Clone Express mix (Vazyme) 5μL <![CDATA[ddH 2 The]]> Make up to 10 μL
[0089] 8) Transform the recombinant product obtained in step 7) into E. coli, pick a single clone and obtain the plasmid pEGFP-fbn1-45bp-2×P2A (plasmid map as shown in Figure 3 As shown), that is, a dual fluorescence reporter system; wherein, Figure 3 The target part marked in the figure is the target mutation sequence. The target gene sequence can be replaced according to the experimental purpose. The target part in this embodiment is the mutation sequence of the FBN1 gene (sequence as Figure 4 shown);
[0090]
[0091] In the dual fluorescence reporter system provided in this embodiment, when a stop codon exists in the inserted gene sequence, the cells only express red fluorescent protein after transfection of the system plasmid; after the stop codon is destroyed using a single editor, the downstream gene continues to be expressed, so that the cells can express red fluorescence and green fluorescence.
[0092] Test example
[0093] This test example tests the screening efficiency of the dual fluorescence reporter system provided in Example 1 for sgRNA. The specific test method and screening results are as follows:
[0094] 1. sgRNA design and plasmid construction:
[0095] 1) Design of sgRNA:
[0096] In this experimental example, 7 sgRNAs were designed according to the sequence of the target gene FBN1 and the editing window of SpRY-ABE8e. The specific sequences are shown in Table 9.
[0097] Table 9 sgRNA sequences
[0098]
[0099]
[0100] 2) Linear vector construction:
[0101] The backbone plasmid pU6-gRNA (constructed by the laboratory, its plasmid map is as follows Figure 5 The enzyme digestion system was shown in Table 2) and the digestion was carried out in a 37°C water bath for 4 hours. Then, agarose gel electrophoresis was performed and the digestion products were recovered using a gel recovery kit (TIANGEN).
[0102] Table 10 Enzyme Digestion System 3
[0103] Components content pU6-gRNA 5μg BbsI(NEB) 3μL 10×Buffer 10μL <![CDATA[ddH 2 The]]> Make up to 100 μL
[0104] 3) Primer annealing:
[0105] The specific sequences of the corresponding primers designed for the 7 sgRNAs are shown in Table 11; the annealing system was prepared according to the formula recorded in Table 12 (taking FBN1-sgRNA1 as an example), reacted at 95°C in a PCR instrument for 10 minutes, and then naturally cooled for several hours.
[0106] Table 11 Primer sequence 3
[0107]
[0108]
[0109] Table 12 Annealing system
[0110] Components content FBN1-g1-F (10 μM) 10μL FBN1-g1-R (10 μM) 10μL 10×NEB buffer 5μL <![CDATA[ddH 2 The]]> Make up to 50 μL
[0111] 4) Ligation: Prepare the ligation system according to the formula in Table 13 (taking FBN1-sgRNA1 as an example), and use Solution I ligase to ligate at 16° C. for more than 1 hour.
[0112] Table 13 Connection system
[0113] Components content pU6-gRNA was digested with BbsI to recover the product 0.8μL Annealing product in step 3) 4.2μL Solution I 5μL
[0114] 5) Transform the ligation product obtained in step 4) and select a single clone for sequencing. The results are as follows: Figure 6 shown by Figure 6 It can be seen that an expression vector connected with sgRNA was prepared in this experimental example.
[0115] 3. Cell transfection:
[0116] In this experimental example, different combinations of plasmids were transfected into HEK293T cells (the transfection system is shown in Table 14), and pCMV-SpRY-ABE8e is an adenine base editor (the plasmid map is shown in Figure 7 shown);
[0117]
[0118] According to the combination recorded in Table 14, the plasmid was transfected into HEK293T cells with a density of about 70% to 80% in a 24-well plate using a liposome transfection reagent. The transfection effect was as follows: Figure 8 , 9 The medium was changed 24 hours after transfection, and cells were collected 48 hours later for flow cytometry sorting to collect cells with both red and green light.
[0119] Table 14 HEK293T cell transfection
[0120]
[0121] Depend on Figure 8 and Fig. 9 It can be seen that when the plasmid expressing the editor and sgRNA is not transferred, HEK293T cells hardly express green fluorescence, which is in line with the expected results of the experiment.
[0122] 4. Editing efficiency detection:
[0123] The cell lysate was amplified by PCR using primers seq-1 and seq-2. The specific PCR system is shown in Table 15, and the specific sequence of the primer pair is shown in Table 16.
[0124] The editing efficiency results were obtained by sequencing. Fig.11 and Fig.12 shown.
[0125] Table 15 PCR system 3
[0126] Components content Cell lysate 1μL seq-1 1μL seq-2 1μL 2×Taq Master Mix (Vazyme) 10μL <![CDATA[ddH 2 The]]> Make up to 20 μL
[0127] Table 16 Primer sequence 4
[0128] name sequence seq-1 5'-GAGGGCCGCCACTCCACCG-3'(SEQ ID NO:28) seq-2 5'-GACACGCTGAACTTGTGGCC-3'(SEQ ID NO:29)
[0129] Depend on Figure 10 to Figure 12 It can be seen that the actual editing efficiency trend of different sgRNAs is close to the trend of the green fluorescence proportion of transfected cells; since a cell may have more than one reporter system plasmid, but only one plasmid needs to be edited to emit green fluorescence, the green fluorescence proportion may be different from the actual editing efficiency, but the overall trend is consistent, indicating that the dual fluorescence reporter system provided by the present invention can reflect the relative editing efficiency of sgRNA to a certain extent; from the screening results, it can be seen that sgRNA2 has the highest editing efficiency, followed by sgRNA1 and sgRNA3, and these three sgRNAs can be used for further FBN1 gene editing experiments.
[0130] The embodiments of the present invention are described in detail above in conjunction with the accompanying drawings, but the present invention is not limited to the above embodiments. Various changes can be made within the knowledge of ordinary technicians in the relevant technical field without departing from the purpose of the present invention. In addition, the embodiments of the present invention and the features in the embodiments can be combined with each other without conflict.
Claims
1. A nucleic acid molecule, characterized in that The nucleic acid molecule comprises, from the 5' end to the 3' end, a first reporter gene encoding a first reporter protein, a target gene fragment and a second reporter gene encoding a second reporter protein.
2. The nucleic acid molecule according to claim 1, characterized in that The first reporter protein and the second reporter protein each independently include luciferase protein or fluorescent protein; Preferably, the first reporter protein and the second reporter protein are different from each other.
3. The nucleic acid molecule according to claim 1, characterized in that The nucleotide sequence of the nucleic acid molecule is shown in SEQ ID NO:
5.
4. Biomaterial, characterized in that The biological material comprises at least one of the following (1) to (7): (1) An expression cassette comprising the nucleic acid molecule according to any one of claims 1 to 3; (2) A vector comprising the nucleic acid molecule according to any one of claims 1 to 3; (3) a vector comprising the expression cassette described in (1); (4) A transgenic cell line comprising the nucleic acid molecule according to any one of claims 1 to 3; (5) a transgenic cell line comprising the expression cassette described in (1); (6) a transgenic cell line comprising the vector described in (2); (7) A transgenic cell line comprising the vector described in (3).
5. A kit, characterized in that: The kit comprises: the nucleic acid molecule according to any one of claims 1 to 3 and / or the biological material according to claim 4.
6. The kit according to claim 5, characterized in that The kit also includes nucleic acid molecules encoding base editing elements and gene editing enzymes.
7. The kit according to claim 6, characterized in that The base editing element comprises adenine deaminase or cytosine deaminase; And / or, the gene editing enzyme includes nCas9.
8. Application of (a) to (c) in evaluating sgRNA-mediated gene editing activity: (a) a nucleic acid molecule as claimed in any one of claims 1 to 3; (b) the biomaterial as claimed in claim 4; (c) The kit according to any one of claims 5 to 7.
9. A method for screening sgRNA, characterized in that: The method uses the kit as described in any one of claims 5 to 7 to screen the sgRNA to be tested.
10. The method according to claim 9, characterized in that The method comprises the following steps: An expression vector containing the nucleic acid molecule as claimed in any one of claims 1 to 3, an expression vector encoding a base editing element and a gene editing enzyme, and an expression vector encoding the sgRNA to be tested are co-transfected into a host cell and cultured; and the fluorescence expression of the host cell is then detected to evaluate the gene editing activity of the sgRNA.
